Press coverage about Arrowhead Pharmaceuticals (NASDAQ:ARWR) has trended somewhat positive on Friday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.9773040338236 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Arrowhead Pharma (ARWR) Technical Fundamentals and Valuation – ExpertGazette (expertgazette.com)
- Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting ® (enhancedonlinenews.com)
- Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting® (finance.yahoo.com)
- Analyst’s Consensus to Buy Signal: Arrowhead Pharmaceuticals, Inc. (ARWR) – Street Observer (press release) (streetobserver.com)
- Traders Alert: Arrowhead Pharmaceuticals, Inc., (NASDAQ:ARWR … – Stocks In The News (press release) (tradingnewsnow.com)
ARWR has been the topic of a number of analyst reports. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, August 24th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price objective (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $2.00.
Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 4.06 on Friday. The firm has a 50 day moving average of $3.53 and a 200 day moving average of $2.14. The firm’s market capitalization is $303.57 million. Arrowhead Pharmaceuticals has a one year low of $1.20 and a one year high of $6.99.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The business had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. Equities analysts forecast that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current year.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.